Nancy Knight
Showing 1–2 of 2 transcripts.
- Milken Institute1h 2m
Outsmarting Superbugs: What Are the Alternatives?
Margaret Hamburg, Matthew Hepburn, Peter Jackson, Nancy Knight, Jeanette Mucha, Peter Piot, Peggy Hamburg, David Wallace, Lance Price
Global leaders and organizations including the WHO, CDC, and the U.K. government are coordinating a multi-faceted response to antimicrobial resistance, which threatens to cause 10 million annual deaths by 2050 and mimic the 2008 financial crisis through massive economic losses. Innovative initiatives such as the CDC's AMR Challenge, Carb-X's $80 million funding for 40 development projects, and the U.K.'s "pull incentive" trial aim to revitalize the antibiotic pipeline by supporting SMEs and rewarding disease prevention rather than sales volume. Despite these advances, experts warn that rigid intellectual property laws, inadequate wastewater treatment, and capital gaps in microbiome startups hinder the deployment of new therapies needed to combat untreatable superbugs like drug-resistant tuberculosis.
- Milken Institute53 min
The Cost of Chronic Disease and the Future of Treatment
Hugh Waters, Hawaa Althahak Almansoori, Sumit Jamuar, Nancy Knight, Freda Lewis-Hall, Hawa Al-Mansouri
The event examines the escalating chronic disease crisis in the MENA region, where obesity and diabetes rates now rival US figures, driving a $20.5 billion economic burden and necessitating advanced mobile surveillance strategies. Experts highlight critical gaps in genomic data representation and clinical reference ranges that risk misdiagnosing non-European populations, while detailing how falling sequencing costs and AI are enabling precision medicine. The panel concludes by advocating a systemic shift from reactive sick care to proactive health systems that prioritize lifestyle modification and predictive prevention to mitigate future disease burdens.